$MMRF @.0289
MMRGlobal to Grant Royalty-Free Licenses to Universities to Research Ebola Therapies Using Company's Patented Monoclonal Antibody Technology
LOS ANGELES, CA--(Marketwired - Aug 5, 2014) - MMRGlobal, Inc. (OTCQB: MMRF) ("MMR"
today announced that the Company plans on granting royalty-free licenses to universities interested in using the Company's patented antibody technology for research and development into potential therapies in the fight against Ebola.
"In response to the humanitarian Ebola crisis, MMR plans on granting the licenses for research into the development of treatments for Ebola and other infectious diseases," said Robert H. Lorsch, MMRGlobal CEO.
MMRGlobal owns technology that allows for the development and use of therapeutics through production of specific monoclonal antibodies. The technology utilizes proprietary Human Framework Reassembly (HuFR) components in the construction of antibodies, which permits the antibodies to retain their beneficial properties while reducing or eliminating the side-effects seen with other antibodies that are due to the body's reaction to foreign substances.
MMRGlobal's biotech intellectual property portfolio includes patents granted in the United States, Australia, South Korea and Mexico directed to "Antibodies and Methods for Making and Using Them." Additional patents for the Company's antibody technology are also pending in the United States, Australia, Brazil, Canada, China, Hong Kong, India, Europe, Japan and South Korea.
MMR's antibody technology has been used to produce anti-CD20 monoclonal antibodies having particular utility in fighting cancers. For additional information, contact Investor Relations at info@mmrmail.com.
About MMRGlobal Biotech Patents and Applications
MMRGlobal owns a portfolio of patents and patent applications for the monoclonal antibody technology, including patents and applications covering anti-CD20 antibodies and their production. U.S. Patent No. 8,465,741 protects various antibodies and the methods for making and using them; additional U.S. patent applications are pending. Foreign protection includes patents in Australia, South Korea and Mexico, along with pending applications in Brazil, Canada, China, Hong Kong, India, Europe, and Japan, all originating from international application PCT/US07/78568. The patents provide further detail of the development, structure, manufacture and established assays belonging to MMRGlobal.
In addition to the patents and patent applications, MMRGlobal assets relating to the anti-CD20 antibodies available for transfer include:
29 antibodies generated using the patented methods (including amino acid and gene sequences)
Protocols for assays used in the antibody discovery program
Anti-CD20 Cellular ELISA and quantitative IgG ELISA
CDC (complement-dependent cytotoxicity)
ADCC (antibody-dependent cell mediated-cytotoxicity)
Apoptosis
Cell Cycle
Glycerol stocks of the antibodies subcloned into a mammalian expression vector
About MMR Health Information Technology Patents and Applications
In addition to MMRGlobal's biotech patents and intellectual property, the Company, through its wholly owned subsidiary MyMedicalRecords, Inc., is a practicing entity and a leading provider of secure and easy-to-use Personal Health Records through the MyMedicalRecords PHR, and MMRPro and MMRProPlus document management and imaging systems for healthcare professionals. MMR currently has 13 issued U.S. health IT patents pertaining to Personal Health Records including U.S. Patent Nos. 8,301,466; 8,352,287; 8,352,288; 8,121,855; 8,117,646; 8,117,045; 8,321,240; 8,498,883; 8,626,532, 8,645,161; 8,725,537; 8,768,725 and 8,775,212, with over 300 claims, as well as additional applications and continuation applications involving inventions pertaining to Personal Health Records, Patient Portals and other Electronic Health Record systems. In addition to the U.S., MMR currently has patents issued, pending and/or applied for in 11 other countries or regional authorities including Australia, Singapore, New Zealand, Mexico, Japan, Canada, Hong Kong, China, South Korea, Israel and Europe.
About MMRGlobal
MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs" and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. The Company's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. visit www.mmrglobal.com. View demos and video tutorials of the Company's products and services at www.mmrtheater.com.
Forward-Looking Statements
All statements in this press release that are not strictly historical in nature, including, without limitation, intellectual property enforcement actions, infringement claims or litigation, intellectual property licenses, and future performance, management's expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "need," "possibility," "potential," "intend," "offer," "development," "if," "negotiate," "when," "begun," "believe," "achieve," "will," "estimate," "expect," "maintain," "plan," and "continue," or the negative of these words. Actual outcomes and results of operations and the timing of selected events may differ materially from the results predicted, and any reported results should not be considered as an indication of future performance. Such statements are necessarily based on assumptions and estimates and are subject to various risks and uncertainties, including those relating to the possible invalidity of the underlying assumptions and estimates and possible changes or developments in economic, business, industry, market, legal and regulatory circumstances and conditions and actions taken or omitted to be taken by third parties, including customers, suppliers, business partners, potential licensees, competitors and legislative, judicial and other governmental authorities and officials. Factors that could cause or contribute to such differences include, but are not limited to: unexpected outcomes with respect to intellectual property enforcement actions, claims of intellectual property infringement and general intellectual property litigation; our ability to maintain, develop, license, and protect our patent portfolio for both the Company's health IT and biotechnology intellectual property assets in the U.S. and internationally; the timing of milestone payments in connection with licensing our intellectual property; our ability to establish and maintain strategic relationships; changes in our relationships with our licensees; the risk the Company's products are not adopted or viewed favorably by the healthcare community and consumer retail market; business prospects, results of operations or financial condition; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; the timing and volume of sales and installations; the length of sales cycles and the installation process; the market's acceptance of new product and service introductions; competitive product offerings and promotions; changes in government laws and regulations and future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; the possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; risks related to a security breach by third parties; risks associated with recruitment and retention of key personnel; other litigation matters; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is providing this information as of the date of this release and, except as required by applicable law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.
CONTACT:
Bobbie Volman
MMRGlobal
bvolman@mmrmail.com
(310) 476-7002, Ext. 7015
Michael Selsman
Public Communications Co.
ms@publiccommunications.biz
(310) 922-7033
Source: Marketwired (August 5, 2014 - 8:35 AM EDT)
News by QuoteMedia
MMRGlobal to Grant Royalty-Free Licenses to Universities to Research Ebola Therapies Using Company's Patented Monoclonal Antibody Technology
LOS ANGELES, CA--(Marketwired - Aug 5, 2014) - MMRGlobal, Inc. (OTCQB: MMRF) ("MMR"
today announced that the Company plans on granting royalty-free licenses to universities interested in using the Company's patented antibody technology for research and development into potential therapies in the fight against Ebola. "In response to the humanitarian Ebola crisis, MMR plans on granting the licenses for research into the development of treatments for Ebola and other infectious diseases," said Robert H. Lorsch, MMRGlobal CEO.
MMRGlobal owns technology that allows for the development and use of therapeutics through production of specific monoclonal antibodies. The technology utilizes proprietary Human Framework Reassembly (HuFR) components in the construction of antibodies, which permits the antibodies to retain their beneficial properties while reducing or eliminating the side-effects seen with other antibodies that are due to the body's reaction to foreign substances.
MMRGlobal's biotech intellectual property portfolio includes patents granted in the United States, Australia, South Korea and Mexico directed to "Antibodies and Methods for Making and Using Them." Additional patents for the Company's antibody technology are also pending in the United States, Australia, Brazil, Canada, China, Hong Kong, India, Europe, Japan and South Korea.
MMR's antibody technology has been used to produce anti-CD20 monoclonal antibodies having particular utility in fighting cancers. For additional information, contact Investor Relations at info@mmrmail.com.
About MMRGlobal Biotech Patents and Applications
MMRGlobal owns a portfolio of patents and patent applications for the monoclonal antibody technology, including patents and applications covering anti-CD20 antibodies and their production. U.S. Patent No. 8,465,741 protects various antibodies and the methods for making and using them; additional U.S. patent applications are pending. Foreign protection includes patents in Australia, South Korea and Mexico, along with pending applications in Brazil, Canada, China, Hong Kong, India, Europe, and Japan, all originating from international application PCT/US07/78568. The patents provide further detail of the development, structure, manufacture and established assays belonging to MMRGlobal.
In addition to the patents and patent applications, MMRGlobal assets relating to the anti-CD20 antibodies available for transfer include:
29 antibodies generated using the patented methods (including amino acid and gene sequences)
Protocols for assays used in the antibody discovery program
Anti-CD20 Cellular ELISA and quantitative IgG ELISA
CDC (complement-dependent cytotoxicity)
ADCC (antibody-dependent cell mediated-cytotoxicity)
Apoptosis
Cell Cycle
Glycerol stocks of the antibodies subcloned into a mammalian expression vector
About MMR Health Information Technology Patents and Applications
In addition to MMRGlobal's biotech patents and intellectual property, the Company, through its wholly owned subsidiary MyMedicalRecords, Inc., is a practicing entity and a leading provider of secure and easy-to-use Personal Health Records through the MyMedicalRecords PHR, and MMRPro and MMRProPlus document management and imaging systems for healthcare professionals. MMR currently has 13 issued U.S. health IT patents pertaining to Personal Health Records including U.S. Patent Nos. 8,301,466; 8,352,287; 8,352,288; 8,121,855; 8,117,646; 8,117,045; 8,321,240; 8,498,883; 8,626,532, 8,645,161; 8,725,537; 8,768,725 and 8,775,212, with over 300 claims, as well as additional applications and continuation applications involving inventions pertaining to Personal Health Records, Patient Portals and other Electronic Health Record systems. In addition to the U.S., MMR currently has patents issued, pending and/or applied for in 11 other countries or regional authorities including Australia, Singapore, New Zealand, Mexico, Japan, Canada, Hong Kong, China, South Korea, Israel and Europe.
About MMRGlobal
MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs"
and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. The Company's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. visit www.mmrglobal.com. View demos and video tutorials of the Company's products and services at www.mmrtheater.com. Forward-Looking Statements
All statements in this press release that are not strictly historical in nature, including, without limitation, intellectual property enforcement actions, infringement claims or litigation, intellectual property licenses, and future performance, management's expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "need," "possibility," "potential," "intend," "offer," "development," "if," "negotiate," "when," "begun," "believe," "achieve," "will," "estimate," "expect," "maintain," "plan," and "continue," or the negative of these words. Actual outcomes and results of operations and the timing of selected events may differ materially from the results predicted, and any reported results should not be considered as an indication of future performance. Such statements are necessarily based on assumptions and estimates and are subject to various risks and uncertainties, including those relating to the possible invalidity of the underlying assumptions and estimates and possible changes or developments in economic, business, industry, market, legal and regulatory circumstances and conditions and actions taken or omitted to be taken by third parties, including customers, suppliers, business partners, potential licensees, competitors and legislative, judicial and other governmental authorities and officials. Factors that could cause or contribute to such differences include, but are not limited to: unexpected outcomes with respect to intellectual property enforcement actions, claims of intellectual property infringement and general intellectual property litigation; our ability to maintain, develop, license, and protect our patent portfolio for both the Company's health IT and biotechnology intellectual property assets in the U.S. and internationally; the timing of milestone payments in connection with licensing our intellectual property; our ability to establish and maintain strategic relationships; changes in our relationships with our licensees; the risk the Company's products are not adopted or viewed favorably by the healthcare community and consumer retail market; business prospects, results of operations or financial condition; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; the timing and volume of sales and installations; the length of sales cycles and the installation process; the market's acceptance of new product and service introductions; competitive product offerings and promotions; changes in government laws and regulations and future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; the possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; risks related to a security breach by third parties; risks associated with recruitment and retention of key personnel; other litigation matters; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is providing this information as of the date of this release and, except as required by applicable law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.
CONTACT:
Bobbie Volman
MMRGlobal
bvolman@mmrmail.com
(310) 476-7002, Ext. 7015
Michael Selsman
Public Communications Co.
ms@publiccommunications.biz
(310) 922-7033
Source: Marketwired (August 5, 2014 - 8:35 AM EDT)
News by QuoteMedia
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
